Skip to main content
. 2023 Jul 22;24(14):11781. doi: 10.3390/ijms241411781

Figure 4.

Figure 4

Assessment of cell death induced by the combined treatment of PTX and SAS in OCCC cell lines. (A) TOV21G, RMG-1, HAC-2 and ES-2 cells were treated with 10 nM PTX and/or 400 μM SAS for 24 h and the cell lysates were probed for anti-cleaved-PARP antibody using Western blot analysis. β-actin was used as the internal control. PTX, paclitaxel; SAS, sulfasalazine. (B) TOV21G, RMG-1, HAC-2 and ES-2 cells were treated with or without 10 nM PTX and 400 μM SAS for 24 h in the absence or presence of ferrostatin-1 (1 μM) and cell viability was assessed using an MTS assay. (C) ES-2 cells were treated with or without 10 nM PTX and 400 μM SAS for 24 h in the absence or presence of Z-VAD-FMK (20 μM) and cell viability was assessed using an MTS assay. Cell viability was calculated from the ratio of the absorbance of cells treated to that of the untreated cells (set as 1) (n = 8). Data are presented as the mean ± SD. * p < 0.05. SAS, sulfasalazine; PTX, paclitaxel; −, without; +, with. N.S.; not significant.